Wiener klinische Wochenschrift
-
Wien. Klin. Wochenschr. · Jul 2021
The role of quantitative HBsAg in patients with HBV DNA between 2000-20,000 IU/ml.
We aimed to determine the contribution of quantitative HBsAg in differentiating chronic infections from chronic hepatitis in HBeAg negative patients with HBV DNA 2000-20,000 IU/ml. ⋯ Our study suggests that the quantitative HBsAg ≤ 1000 IU/ml limit value might be used for the diagnosis of chronic infection not only in HBV DNA ≤ 2000 IU/ml but also in patients with HBV DNA between 2000-20,000 IU/ml. In addition, antiviral treatment could be considered in patients with quantitative HBsAg > 20,000 IU/ml and HBV DNA > 2000 IU/ml without further examinations such as liver biopsy.
-
Wien. Klin. Wochenschr. · Jul 2021
Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
To assess the adherence to treatment, sustained virologic response (SVR) rate, and reinfection rate in hepatitis C patients with and without intravenous drug use. ⋯ To achieve elimination of hepatitis C better treatment strategies are needed, especially in PWIDs.
-
Wien. Klin. Wochenschr. · Jul 2021
Case ReportsFlavonifractor plautii bloodstream infection in an asplenic patient with infectious colitis.
Flavonifractor plautii is a gram-positive, strictly anaerobic, rod-shaped bacterium. It belongs to the family of Clostridiales, is frequently found in the human gut microbiome and is rarely isolated in other human specimens. ⋯ Asplenia and a damaged intestinal wall might have favored the bloodstream infection. We found similarities in attributes of the affected patients and in treatment patterns between our case and the only three other published case reports.